Skip to main content
SpringerLink
Log in

Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1

  • Preclinical
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Harringtonine (HT) is a new antitumor agent reported to be active in patients with leukemia and lymphoma. The interaction of HT with various antitumor agents was studied in vitro using a human acute myelogenous leukemia cell line KG-1. For the analysis of the drug-drug interaction at the cellular level, Steel proposed the concept of an envelope of additivity. Using this concept, the effect of a two drug combination can be classified as supraadditive (enhancement of the effect), non-interactive (additive), subadditive, and protective (antagonistic). Combination of HT and cytosine arabinoside or HT and dexamethasone produced only additive effects. Combination of HT and methotrexate was subadditive. For HT plus adriamycin or HT plus 5-fluorouracil, data points indicated both subadditive and protective interaction. HT plus acivicin or HT plus L-asparaginase combinations were found to be protective of each other. None of the seven agents produced supraadditive interaction. These results may provide the basis for selecting sequential rather than concurrent combinations which include HT for the treatment of leukemia in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Powell RG, Weisleder D, Smith CR Jr: Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity. J Pharmaceut Sci 61:1227–1230, 1972

    Google Scholar 

  2. Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking: The antitumor effects and pharmacologic actions of harringtonine. Chin Med J 3:131–136, 1977

    Google Scholar 

  3. Powell RG, Weisleder D, Smith CR Jr, Wolff IH: Structure of cephalotaxine and related alkaloids. Tetrahedron Letters, 4081–4084, 1969.

  4. Powell RG, Weisleder D, Smith CR Jr, Rohwedder WK: Structures of harringtonine, isoharringtonine and homoharringtonine. Tetrahedron Letters, 815–818, 1970

  5. Huang MT: Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11:511–519, 1975

    Google Scholar 

  6. Cephalotaxus Research Coordinating Group: Cephalotaxus esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 2:263–272, 1976

    Google Scholar 

  7. Chinese People's Liberation Army 187th Hospital: Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J 3:319–324, 1977

    Google Scholar 

  8. Steel GG: Terminology in the description of drug-radiation interaction. Int J Radiat Oncol 5:1145–1150, 1979

    Google Scholar 

  9. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy — chemotherapy: the concept of additivity. Int J Radiat Oncol 5:85–91, 1979

    Google Scholar 

  10. Koeffler HP, Golde DW: Acute myelogenous leukemia: A human cell line responsive to colony-stimulating activity. Science 200:1153–1154, 1978

    Google Scholar 

  11. Sartorelli AC: Approaches to the combination chemotherapy of transplantable neoplasms. Prog Exp Tumor Res 6:228–288, 1965

    Google Scholar 

  12. Frei E III: Combination cancer therapy: Presidential address. Cancer Res 32:2593–2607, 1972

    Google Scholar 

  13. DeVita VT, Schein PS: The use of drugs in combination for the treatment of cancer: Rationale and results. N Engl J Med 288:988–1006, 1973

    Google Scholar 

  14. Valeriote F, Lin HS: Synergistic interaction of anticancer agents: A cellular perspective. Cancer Chemotherap Rep (Part 1) 59:895–900, 1975

    Google Scholar 

  15. Loewe S, Muischnick H: Uber Kombinationswirkungen #i. Mitteilung: Hilfsmittel der Fragestellung. Arch exper Path Pharm 114:313–347, 1926

    Google Scholar 

  16. Berenbaum MC: Synergy, additivism and antagonism in immunosuppression: A critical review. Clin Exp Immunol 28:1–18, 1977

    Google Scholar 

  17. Capizzi RL: Improvement in the therapeutic index of methotrexate (NSC-740) by L-asparaginase (NSC-109229). Cancer Chemotherap Rep (Part 3) 6:37–41, 1975

    Google Scholar 

  18. Laster WR, Trader MW, Schabel FM Jr, Corbett TH, Girsward DP Jr: Therapeutic synergism of homoharringtonine plus 5-fluorouracil against leukemia P388 (P388/0) and ara-C resistant P388 (P388/Ara-C). (Abstract) Proc Am Assoc Cancer Res 23:199, 1982

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mt. Sinai School of Medicine, 10029, New York, NY, U.S.A.

    Tsuyoshi Okano,  Takao Ohnuma & James F. Holland

  2. UCLA School of Medicine, University of California, Los Angeles, California, U.S.A.

    H. Phillip Koeffler

  3. Institute of Materia Medico, Chinese Academy of Medical Sciences, Beijing, China

    Han Jui

Authors
  1. Tsuyoshi Okano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takao Ohnuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James F. Holland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Phillip Koeffler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Han Jui
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okano, T., Ohnuma, T., Holland, J.F. et al. Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. Invest New Drugs 1, 145–150 (1983). https://doi.org/10.1007/BF00172073

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172073

Key words

Search

Navigation